A Phase 1 interventional study of Amicidin-β topical solution - 15 mL and Amicidin-β topical solution - 50 mL in Surgical Wound Infection, Traumatic Wound Infection and Cutaneous Abscess, sponsored by Macro Biologics, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Macro Biologics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.
Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 134th largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 16 of the 33 other live ones, and was the 196th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Riverside University Health System Medical Center · Sites in United States
Ages 18+ · Women only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Rhode Island Hospital · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 15 · Phase 3 33 · Phase 4 39
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is below the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 208 across the 177 interventional studies, 300 across the 23 observational. Of the 144 that completed or were terminated, 78 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 202 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Macro Biologics, Inc. as lead sponsor.
Macro Biologics, Inc. has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
12 of the studies in Surgical Wound Infection with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06014411Hospital for Special Surgery, New YorkEarly Versus Delayed Bathing of Orthopaedic Surgical Wounds | 2026-12 |
| NCT04773457Boston Children's HospitalNeutrophil Phenotypic Profiling and Surgical Site Infections in Surgical Patients | 2026-12-01 |
| NCT04725916Sean DevittStudying How Outpatient Water affEcts Risks With Drains (SHOWER Study) | 2026-12-15 |
| NCT06378359University of MinnesotaEffectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients | 2026-12-31 |
| NCT07379684Macro Biologics, Inc.A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 202 studies in Surgical Wound Infection with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into contaminated or infected surgical or traumatic wounds or cutaneous abscess during a surgical procedure. The main questions it aims to answer are:
This is a Standard of Care (SOC)- controlled study of approximately 44 patients divided into three sequential cohorts of 8, 12, and 24 patients. Within each sequential cohort, patients will be randomized to SOC only or to SOC plus Amicidin-β topical solution in a 1:3 ratio.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Main Inclusion Criteria:
Surgical or traumatic wound ≤90 days old or a cutaneous abscess that is:
Main Exclusion Criteria:
Patients with any of the following will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to Standard of Care (SOC), patients will receive Amicidin-β topical solution - 15 mL immediately prior to wound closure/dressing, with rinsing out with saline.
Drug: Amicidin-β topical solution - 15 mL · Drug: Standard of Care (SOC)
In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, with rinsing out with saline
Drug: Amicidin-β topical solution - 50 mL · Drug: Standard of Care (SOC)
In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, without rinsing out with saline
Drug: Amicidin-β topical solution - 50 mL · Drug: Standard of Care (SOC)
Patients will receive Standard of Care (SOC) only
Drug: Standard of Care (SOC)
Amicidin-β topical solution for local administration - 15 mL
Amicidin-β topical solution for local administration - 50 mL
Per institutional Standard Of Care
Overall comparison of treatment emergent adverse events (TEAES) of combined SOC + Amicidin-β topical solution recipients to SOC only recipients across 3 cohorts.
Time frame: From Day 1 to Day 30
Number of participants with Treatment Emergent Adverse Events (TEAEs) by severity according to the study protocol.
Time frame: From Day 1 to Day 30
Measurement of systemic absorption of Amicidin-β recipients.
Systemic absorption will be assessed by single molecule array (Simoa) immunoassay measurements of patient plasma.
Time frame: From Day 1 to Day 3
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.